

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1 through 6 canceled.

7. (Currently Amended) A method of inhibiting migration of human microvascular endothelial cells (HMVECs) expressing a native Robo-4 receptor, the method comprising exposing said HMVECs to a Slit ligand, wherein exposing said HMVECs to said Slit ligand inhibits migration of said HMVECs.

8. (Previously Presented) The method of claim 7, wherein exposing said HMVECs to a Slit ligand comprises exposing said HMVECs to a Slit2 ligand.

9. (Previously Presented) The method of claim 8, wherein exposing said HMVECs to a Slit2 ligand comprises exposing said HMVECs to a human Slit2 ligand or a HMVEC migration inhibiting fragment thereof.

Claims 10 through 18 canceled.

19. (Currently Amended) A method of preventing angiogenesis by requiring the migration of HMVECs, the method comprising, inhibiting migration of HMVECs expressing a native Robo-4 receptor, wherein inhibiting migration of said HMVECs comprises providing a Slit ligand and exposing said HMVECs to said Slit ligand such that migration of said HMVECs is inhibited.

20. (Previously Presented) The method of claim 19, wherein providing a Slit ligand comprises providing a Slit2 ligand.

21. (Previously Presented) The method of claim 20, wherein providing a Slit2 ligand comprises providing a human Slit2 ligand or a HMVEC migration inhibiting fragment thereof.

Claim 22 canceled.